Status
Acquired by Tekmira Pharmaceuticals on March 28, 2008
Funding Received
$8.3 Million in 2 Rounds from 4 Investors
Headquarters:
Seattle, WA
Description:
Protiva Biotherapeutics is a biotechnology company developing nucleic acid based pharmaceutical products.
Categories:
Biotechnology
Website:
http://www.protivabio.com

Company Details

Update
Founded:
2000
Employees:
2 in CrunchBase

Protiva Biotherapeutics, Inc., a development stage biotechnology company, develops nucleic acid based pharmaceutical products. The company focuses on developing products to fight various human diseases, such as cancer, influenza, Ebola, inflammatory diseases, and chronic viral infections. Its products include Pro 1, a tumor cell growth inhibitor, which kills tumor cells and inhibits tumor growth; Pro-101, an siRNA product that acts to inhibit the production of a protein involved in tumor growth; Pro-B, which acts to inhibit the expression of a protein, apolipoprotein B; Pro-EBOV and Pro-MARV that act to inhibit the replication of the Ebola and Marburg viruses; and Stable Nucleic-Acid Lipid Particle technology, an encapsulation and delivery system for nucleic acid payloads, such as short interfering RNA (siRNA), to target cells. The company also develops Hepatitis siRNA products for the treatment of hepatitis B and C. Protiva Biotherapeutics, Inc. has a research and development facility in Vancouver, Canada. The company was founded in 2000 and is based in Seattle, Washington. As of May 30, 2008, Protiva Biotherapeutics, Inc. operates as a subsidiary of Tekmira Pharmaceuticals Corp.

Investors (4)

Update

Offices/Locations (1)

Update
  • Office

    1127 41st Avenue East

    Seattle, WA 98112

    USA

News (3)

Update